Last reviewed · How we verify
Slit One
Slit One is a drug that works by inhibiting the action of a specific protein.
Slit One is a drug that works by inhibiting the action of a specific protein. Used for Phase 3 clinical trials for Slit One are ongoing, but no specific indications have been reported..
At a glance
| Generic name | Slit One |
|---|---|
| Also known as | Slitone (Alk Abello) |
| Sponsor | ASST Fatebenefratelli Sacco |
| Modality | Biologic |
| Phase | Phase 3 |
Mechanism of action
The exact mechanism of action of Slit One is not well understood, but it is believed to involve the inhibition of a protein that plays a key role in a specific cellular process.
Approved indications
- Phase 3 clinical trials for Slit One are ongoing, but no specific indications have been reported.
Common side effects
- Unknown
Key clinical trials
- Evaluation of a Digital Tool to Improve Aeroallergen Immunotherapy Adherence. NavigAITme Project (NA)
- Comparison of Methods for Assessing Intraocular Lens Position
- Automated Applanation Tonometry - Updated (NA)
- Chromosome 18 Clinical Research Center
- Identification of Cellular Biomarkers of Rare Eye Diseases in Adults (NA)
- Evaluating a New Sensor That Measures the Health of the Retina in Normally-sighted Subjects (EARLY_PHASE1)
- A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivitis (PHASE2)
- Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Slit One CI brief — competitive landscape report
- Slit One updates RSS · CI watch RSS
- ASST Fatebenefratelli Sacco portfolio CI